OnCo

Stay in the loop

Leave your email and OnCo will write when something big changes in cancer research. No spam, one click to unsubscribe.

Email updates open shortly. Until then, press Watch on any page to keep it on your list.

drugsTreatmentApproved2022🇨🇳

Linperlisib

aka Yinlijia

Linperlisib is Shanghai Yingli's PI3K-delta inhibitor, approved in China in 2022 for relapsed or refractory follicular lymphoma after two or more lines.